Hepatitis C, HIV, Antibiotics And Vaccines Headline Infectious Diseases Discussion At TAP Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
In developing the infectious diseases track for this year’s Therapeutic Area Partnerships conference, planners focused on areas of unmet medical need, market potential, companies with a diversity of indications, strong science and multi-level partnering opportunities.
You may also be interested in...
TREM Rx Pursues New Vaccine Science
A paper published in Nature reveals the paradigm-shifting science of TremRx’s vaccine technology.
Somewhat Late To The HCV Race, Novartis Licenses NS5A Inhibitor From Enanta
The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Roche will combine Anadys' experimental non-nucleoside polymerase inhibitor with its own protease inhibitor and nucleoside in the effort to establish an all-oral combination therapy for hepatitis C.